RxDoctor Payments DataLook up a doctor →

Luke Webb, MD

Internal Medicine · Colorado Springs, CONPI 1932161916

Payments from drug & device makers

$2,062,557in general payments, 2019–2025

Across 1,054 payments — averaging $1956.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$485K
  • GSK$426K
  • AstraZeneca$326K
  • Pfizer$319K
  • Regeneron$191K
  • Eli Lilly$177K
  • plus $138K from 34 others

What the payments were for

  • Consulting fees$20,8267%
  • Speaking & faculty fees$223,55078%
  • Travel & lodging$25,5819%
  • Food & beverage$17,1486%
  • Education$1830%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,062,557 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.

See all internal medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$289,501
Medicare patients
213
Services billed
11,204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab41$157,646
TezspireTezepelumab-Ekko34$141,625
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$42,244
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$17,570
Spiriva RespimatTiotropium Bromide13$11,810
SymbicortBudesonide/Formoterol Fumarate26$9,332
Breo ElliptaFluticasone/Vilanterol14$9,231
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$4,173
Epinephrine16$4,138
Advair HfaFluticasone Propion/Salmeterol13$4,071
Ipratropium Bromide39$1,744
Azelastine Hcl36$1,549
Montelukast Sodium152$1,485
Albuterol Sulfate HfaAlbuterol Sulfate45$1,274
Fluticasone Propionate34$601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$326,478$168,52782 claims
GSKTrelegy Ellipta, Breo Ellipta$425,638$51,47568 claims
Boehringer IngelheimSpiriva Respimat$91$11,81013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,430 internal medicine providers in Colorado.

Other internal medicine in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →